LIN, Gloria Hoi Ying,VILLER, Natasja Nielsen,WONG, Mark Michael,UGER, Robert Adam
申请号：
AU2019235627
公开号：
AU2019235627A1
申请日:
2019.03.08
申请国别(地区):
AU
年份:
2020
代理人:
摘要：
CD47+ disease cells such as cancer cells are treated using a combination of CD47 blocking agent and an EGFR antibody such as cetuximab. The anti-cancer effect of cetuximab is enhanced in the presence of SIRPαFc. Specific combinations include SIRPαFc forms that comprise an Fc that is either IgGl or preferably IgG4 isotype. These combinations are useful particularly to treat solid tumours and blood cancers including lymphomas, leukemias and myelomas.
